You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Alembic Pharma receives final approval for OCD treatment drug

Capital Market 

Alembic Pharmaceuticals on Thursday announced that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Anafranil Capsules of SpecGX LLC. Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

According to IQVIA, Clomipramine Hydrochloride Capsules USP have an estimated market size of $32 million for twelve months ending June 2021. Alembic has a cumulative total of 149 ANDA approvals from USFDA.

Shares of Alembic Pharma were trading 1.07% lower at Rs 778 on BSE.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, August 05 2021. 12:04 IST